PMID- 21323962
OWN - NLM
STAT- MEDLINE
DCOM- 20110712
LR  - 20220310
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Print)
IS  - 0309-0167 (Linking)
VI  - 58
IP  - 3
DP  - 2011 Feb
TI  - HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit 
      monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH 
      and SISH).
PG  - 383-94
LID - 10.1111/j.1365-2559.2011.03760.x [doi]
AB  - AIMS: HER2 gene amplification has been detected in 10-20% of gastric 
      adenocarcinomas. In view of the recently demonstrated clinical benefit of the 
      anti-human epidermal growth factor receptor 2 (HER2) drug trastuzumab in the 
      treatment of advanced gastric cancer, reliable HER2 testing is of key importance. 
      The aim of this study was to examine HER2 status in gastro-oesophageal 
      adenocarcinomas comparing SP3 and 4B5 immunohistochemistry (IHC) with dual probe 
      HER2 [fluorescence in situ hybridization (FISH) and silver in situ hybridization 
      (SISH)]. METHODS AND RESULTS: IHC and SISH were carried out on biopsy specimens 
      of 146 patients with adenocarcinomas of the oesophagus and stomach. All 
      SP3-IHC-positive cases and 91% of 4B5-IHC-positive cases were amplified. 
      Sensitivity of SP3-IHC-positivity and 4B5-IHC-positivity for amplification was 
      77% and 96%, respectively. Results of FISH performed in 42 cases were identical 
      to SISH. Amplification was heterogeneous in 73% of the adenocarcinomas; 24% of 
      the oesophago-gastric carcinomas and 7% of distal stomach tumours were amplified. 
      CONCLUSIONS: HER2-positivity is present in a significant proportion of 
      oesophago-gastric adenocarcinomas (24%), but at a lower rate in the distal 
      stomach (7%). Sensitivity for amplification is higher with 4B5 IHC than with SP3. 
      FISH and SISH yield identical results, but assessment is much easier with SISH. 
      Our findings provide important guidance for HER2-testing in gastro-oesophageal 
      adenocarcinomas for patients in whom anti-HER2 treatment is considered.
CI  - (c) 2011 Blackwell Publishing Limited.
FAU - Boers, James E
AU  - Boers JE
AD  - Department of Pathology, Isala klinieken, Zwolle, the Netherlands. 
      j.e.boers@isala.nl/j.e.boers@me.com
FAU - Meeuwissen, Harriette
AU  - Meeuwissen H
FAU - Methorst, Natalie
AU  - Methorst N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110216
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Antibodies, Monoclonal)
RN  - 3M4G523W1G (Silver)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*metabolism/pathology
MH  - Antibodies, Monoclonal
MH  - Esophageal Neoplasms/*metabolism/pathology
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/genetics/immunology/*metabolism
MH  - Silver/chemistry
MH  - Stomach Neoplasms/*metabolism/pathology
PMC - PMC3085073
EDAT- 2011/02/18 06:00
MHDA- 2011/07/13 06:00
CRDT- 2011/02/18 06:00
PHST- 2011/02/18 06:00 [entrez]
PHST- 2011/02/18 06:00 [pubmed]
PHST- 2011/07/13 06:00 [medline]
AID - 10.1111/j.1365-2559.2011.03760.x [doi]
PST - ppublish
SO  - Histopathology. 2011 Feb;58(3):383-94. doi: 10.1111/j.1365-2559.2011.03760.x. 
      Epub 2011 Feb 16.